35 / 52
VOLUME 13 NUMBER 2 • DECEMBER 2016
85
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
Also, the long-term safety of the use of these cells in humans must
be explored, initially by the development of the appropriate animal
models. Stem-cell therapy is already available for the treatment of
haematological malignancies in specialised medical centres within
Africa
139
and therefore it is feasible that the therapeutic use of
ADSCs may also become a reality for this continent.
Conclusion
Our view of adipose tissue has changed over time. Additional
information has led us to confirm that fat is not only a store of
energy, but when in excess, it is the instigator of obesity-related
co-morbidities. The characterisation of adipokines has led to the
realisation that adipose tissue is a true endocrine organ, and the
isolation and use of ADSCs has led to hope for future therapeutic
treatments of degenerative diseases of fat, bone, muscle and
cartilage. Once fat was just fat, but it is now much more than
that.
References
1. Mathers CD, Boerma T, Ma FD. Global and regional causes of death.
Br Med Bull
2009;
92
: 7–32.
2. Tipton CM. Historical perspective: the antiquity of exercise, exercise physiology
and the exercise prescription for health. Wld Rev Nutr Diet 2008; 98: 198–245.
3. Cheng TO. Hippocrates and cardiology.
Am Heart J
2001;
141
: 173–183.
4. Woodhouse R. Obesity in art: a brief overview.
Front Horm Res
2008;
36
: 271–
286.
5. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the
United States: prevalence and trends, 1960–1994.
Int J Obes Relat Metab Disord
1998;
22
: 39–47.
6. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence
of overweight and obesity in the United States, 1999–2004.
J Am Med Assoc
2006;
295
: 1549–1555.
7. Abubakari AR, Lauder W, Agyemang C, Jones M, Kirk A, Bhopal RS. Prevalence
and time trends in obesity among adult West African populations: a meta-
analysis.
Obes Rev
2008;
9
: 297–311.
8. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and
the consequences? The trends in obesity and chronic disease in China.
Int J Obes
(Lond) 2007;
31
: 177–188.
9. Holdsworth M, Gartner A, Landais E, Maire B, Delpeuch F. Perceptions of healthy
and desirable body size in urban Senegalese women.
Int J Obes Relat Metab
Disord
2004;
28
: 1561–1568.
10. Kissebah AH, Krakower GR. Regional adiposity and morbidity.
Physiol Rev
1994;
74
: 761–811.
11. Hamdy O, Porramatikul S, Al Ozairi E. Metabolic obesity: the paradox between
visceral and subcutaneous fat. Curr Diabetes Rev 2006; 2: 367–373.
12. Frayn KN. Visceral fat and insulin resistance – causative or correlative?
Br J Nutr
2000;
83
(Suppl 1): S71–S77.
13. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why
might South Asians be so susceptible to central obesity and its atherogenic
consequences? The adipose tissue overflow hypothesis.
Int J Epidemiol
2007;
36
(1): 220–225.
14. Sjostrom L, William-Olsson T. Prospective studies on adipose tissue development
in man.
Int J Obes
1981;
5
: 597–604.
15. Couillard C, Mauriege P, Imbeault P, Prud’homme D, Nadeau A, Tremblay A,
et
al
. Hyperleptinemia is more closely associated with adipose cell hypertrophy than
with adipose tissue hyperplasia.
Int J Obes Relat Metab Disord
2000;
24
: 782–
788.
16. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in
the pathogenesis of nonalcoholic fatty liver disease.
Liver Int
2007;
27
: 423–
433.
17. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of
fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2
diabetes mellitus.
Ann N Y Acad Sci
2002;
967
: 363–378.
18. Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage
in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases.
Int J Obes Relat Metab Disord
2004;
28
(Suppl 4): S58–S65.
19. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose
tissue and insulin resistance.
Curr Opin Lipidol
2007;
18
: 240–245.
20. Mertens I, Verrijken A, Michiels JJ, Van der PM, Ruige JB, Van Gaal LF. Among
inflammation and coagulation markers, PAI-1 is a true component of the
metabolic syndrome.
Int J Obes
(Lond) 2006;
30
: 1308–1314.
21. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor
alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1
secretion from subcutaneous and omental human fat cells in suspension culture.
Metabolism
2000;
49
: 666–671.
22. Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance.
Diabetes Metab
1991;
17
: 96–100.
23. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M,
et al
. Plasma
angiotensinogen concentrations in obese patients.
Am J Hypertens
1997;
10
:
629–633.
24. Van H, V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased
adipose angiotensinogen gene expression in human obesity.
Obes Res
2000;
8
:
337–341.
25. Giacchetti G, Faloia E, Sardu C, Camilloni MA, Mariniello B, Gatti C,
et al
. Gene
expression of angiotensinogen in adipose tissue of obese patients.
Int J Obes
Relat Metab Disord
2000;
24
(Suppl 2): S142–S143.
26. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM,
et al
.
Adipose angiotensinogen is involved in adipose tissue growth and blood pressure
regulation.
Fed Am Soc Exp Biol J
2001;
15
(14): 2727–2729.
27. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, Buerke M,
et
al
. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk
for coronary artery disease.
Circ J
2005;
69
: 1484–1489.
28. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD,
et al
. Resistin promotes
endothelial cell activation: further evidence of adipokine-endothelial interaction.
Circulation
2003;
108
: 736–740.
29. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV,
et al
.
Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-
activated receptor-gamma action in humans.
Diabetes
2001;
50
: 2199–2202.
30. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S,
et al
. Resistin
is not associated with insulin sensitivity or the metabolic syndrome in humans.
Diabetologia
2005;
48
: 2330–2333.
31. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue.
Nature
1994;
372
:
425–432.
32. Ahima RS. Revisiting leptin’s role in obesity and weight loss.
J Clin Invest
2008;
118
: 2380–2383.
33. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D,
et al
. Leptin
stimulates fatty-acid oxidation by activating AMP-activated protein kinase.
Nature
2002;
415
: 339–343.
34. Muoio DM, Dohm GL, Fiedorek FT, Jr, Tapscott EB, Coleman RA. Leptin directly
alters lipid partitioning in skeletal muscle.
Diabetes
1997;
46
: 1360–1363.
35. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin
resistance.
A Rev Physiol
2008;
70
: 537–556.
36. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and
metabolism.
Gastroenterology
2007;
132
: 2103–2115.
37. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ.
J Clin Endocrinol
Metab
2004;
89
: 2548–2556.
38. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA
cloning and expression of a novel adipose specific collagen-like factor, apM1
(AdiPose Most abundant Gene transcript 1).
Biochem Biophys Res Commun
1996;
221
: 286–289.
39. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein
similar to C1q, produced exclusively in adipocytes.
J Biol Chem
1995;
270
:
26746–26749.
40. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y,
et
al
. Secretion of adiponectin and regulation of apM1 gene expression in human
visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102–1107.
41. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J,
et al
. Paradoxical
decrease of an adipose-specific protein, adiponectin, in obesity.
Biochem Biophys
Res Commun
1999;
257
: 79–83.
42. Brichard SM, Delporte ML, Lambert M. Adipocytokines in anorexia nervosa: a
review focusing on leptin and adiponectin.
Horm Metab Res
2003;
35
: 337–
342.
43. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE,
et al
.
Hypoadiponectinemia in obesity and type 2 diabetes: close association with
insulin resistance and hyperinsulinemia.
J Clin Endocrinol Metab
2001;
86
: 1930–
1935.
44. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC,
et al
.
Circulating concentrations of the adipocyte protein adiponectin are decreased in
parallel with reduced insulin sensitivity during the progression to type 2 diabetes
in rhesus monkeys.
Diabetes
2001;
50
: 1126–1133.